172.85
1.06%
+1.82
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BGNE Giù?
Forum
Previsione
BeiGene Ltd ADR Borsa (BGNE) Ultime notizie
BeiGene shares price target raised on Brukinsa robust launch - Investing.com
Investing.com
BeiGene stock price target lowered by Jefferies despite sales growth - Investing.com
Investing.com
BeiGene shares edge up on narrower-than-expected loss in Q1, revenue beat - Investing.com
Investing.com
BeiGene shares get price target bump on recent collaboration developments By Investing.com - Investing.com UK
Investing.com UK
Evaluating BeiGene: Insights From 6 Financial Analysts
Benzinga
BeiGene Ltd ADR [BGNE] Investment Appeal on the Rise – Knox Daily - Knox Daily
Knox Daily
BeiGene CEO John Oyler sells shares worth over $7.4 million - Investing.com
Investing.com
4 Analysts Assess BeiGene: What You Need To Know
Benzinga
Lululemon Issues Weak Outlook, Joins Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Benzinga
BofA raises BeiGene stock target to $179.30 on strong drug sales growth - Investing.com
Investing.com
BeiGene CEO John Oyler sells shares worth over $8.3 million - Investing.com
Investing.com
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
Benzinga
Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments
Seeking Alpha
UBS cuts BeiGene stock target to $285.70, maintains Buy rating - Investing.com
Investing.com
BeiGene reports Q4 earnings beat, record annual revenue - Investing.com
Investing.com
BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?
Zacks Investment Research
BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards? - Nasdaq
Nasdaq
JP Morgan's Bullish View On This Chinese Biotech, Says Pullback Creates Entry Point
Benzinga
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
The Motley Fool
As China's Population Declines In 2023, Will Aging Demographics Boost Healthcare Stocks?
Benzinga
3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024
Zacks Investment Research
Top 5 Momentum Picks for January After a Fabulous 2023
Zacks Investment Research
New Strong Buy Stocks for December 22nd
Zacks Investment Research
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
Zacks Investment Research
5 Nasdaq Composite Laggards Likely to Gather Pace in 2024
Zacks Investment Research
The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics
Zacks Investment Research
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
Zacks Investment Research
Primecap Odyssey Funds' 2023 Semiannual Letter - GuruFocus.com
GuruFocus.com
Weekly Upgrades and Downgrades - InvestorPlace
InvestorPlace
BeiGene shares drop after AbbVie unit files patent-infringement lawsuit over cancer drug - MarketWatch
MarketWatch
Making it harder to "buy" China, Inc. | US-China Institute - US-China Institute
US-China Institute
What Happens to Your ETFs if Chinese ADRs Delist? - Morningstar HK
Morningstar HK
Are Delistings of Chinese Stocks on Their Way? - Morningstar
Morningstar
US-Listed Chinese Companies React To Today's HFCAA Announcement & Fading Optimisim On Ukraine Truce - Forbes
Forbes
BeiGene stock: Buy or sell China's cancer-fighting Pharma giant? - Asia Markets
Asia Markets
Novartis (NVS) Collaborates With BeiGene for Oncology Drug - Yahoo Movies UK
Yahoo Movies UK
See What the Public Investment Fund Bought Recently Including Walmart and FedEx Stocks - SWFI - Sovereign Wealth Fund Institute
Sovereign Wealth Fund Institute
Dow Jones Industrial Average Futures Drop After ADP Payrolls Miss - Schaeffers Research
Schaeffers Research
Capitalizzazione:
|
Volume (24 ore):